Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors

Inclusion Criteria: 1. Histologically confirmed malignant solid tumor and not a candidate for known regimens or protocol treatments of higher efficacy or priority 2. Failed conventional therapy for their cancer or have a malignancy for which a conventional therapy does not exist 3. Recovered from all acute adverse effects of prior therapies, excluding alopecia (hair loss) 4. ECOG performance status of 0, 1, or 2 5. 18 years of age or older 6. Normal organ and bone marrow function as defined by: * absolute neutrophil count greater than or equal to 1,500 cells/microliter * platelets greater than or equal to 100,000 cells/microliter * total bilirubin within normal institutional limits * AST (SGOT)/ALT (SGPT) less than or equal to 2.5 x institutional upper limit of normal (ULN) or less than or equal to 5.0 x ULN in patients with liver metastases * plasma creatinine less than or equal to 1.5 x institutional ULN OR * creatinine clearance greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal 7. Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: 1. Previously treated with irinotecan, or had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study, or not recovered from adverse effects due to agents administered more than 4 weeks earlier 2. Receiving any other investigational agent 3. Known brain metastases 4. History of allergic reactions attributed to compounds of similar chemical composition to IHL-305 5. Concurrent serious infections (i.e., requiring an intravenous antibiotic) 6. Pregnant women or women of childbearing potential and not using methods to avoid pregnancy; a negative pregnancy test (urine or serum) must be documented at baseline for women of childbearing potential; no breast-feeding while on study. 7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements 8. Significant cardiac disease including heart failure that meets New York Heart Association (NYHA) class III and IV definitions; history of myocardial infarction within one year of study entry; uncontrolled dysrhythmias; or poorly controlled angina. 9. History of serious ventricular arrhythmia (ventricular tachycardia \[VT\] or ventricular fibrillation \[VF\], greater than or equal to 3 beats in a row); QTc greater than or equal to 450 msec for men and 470 msec for women; or left ventricular ejection fraction (LVEF) less than or equal to 40% by multi-gated acquisition scan (MUGA).